InvestSMART

Price-sensitive announcement not found.

Prescient Therapeutics Limited (ASX:PTX)

ALERT: Price-sensitive ASX Announcement for PTX
Current share price for PTX : $0.073 0.03 (69.77%)+
Announcement
Release
20 Aug 2025 4:29PM
Price at Release
$0.043
Full Release
download
Summary
Prescient Therapeutics Limited (PTX) has released its Appendix 4E and Annual Report for the financial year ended 30 June 2024, outlining the company’s operations, financial performance, and major developments during the period. The report highlights PTX's ongoing focus on the advancement of its targeted cancer therapies, particularly its OmniCAR and CellPryme platforms, and provides updates on clinical trials, research partnerships, intellectual property developments, and the company's financial position. The company experienced significant research and development expenditure as it advanced its pipeline, resulting in a reported net loss for the year. PTX emphasizes its commitment to innovation, the development of next-generation cell therapies, and the creation of value for shareholders through strategic investment in its proprietary technologies. The report also includes details on corporate governance, risk management practices, sustainability initiatives, and the outlook for future growth as PTX continues to progress its clinical and preclinical programs.
Key Points
  • Prescient Therapeutics Limited released its Appendix 4E and Annual Report for the year ended 30 June 2024.
  • The company is focused on developing targeted cancer therapies, with primary emphasis on its OmniCAR and CellPryme platforms.
  • Significant progress was made in clinical trials and research partnerships during the reporting period.
  • PTX reported continued investment in research and development, leading to a net loss for the year.
  • Updates on intellectual property, including patent filings and portfolio expansion, are provided.
  • The report details the company’s corporate governance, risk management, and sustainability initiatives.
  • PTX remains committed to innovation and value creation for shareholders.
  • Outlook for future growth is positive, with ongoing clinical and preclinical development of proprietary technologies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.